Revolution Medicines News

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

TipRanksMay 14 07:56 ET

Express News | HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $44 Price Target

BenzingaMay 13 06:33 ET

Buy Rating on Revolution Medicines With a $44 Target Amid Strong Financials and Upcoming Clinical Catalysts

TipRanksMay 13 06:27 ET

Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...

Yahoo FinanceMay 10 12:37 ET

Health Check: How Prudently Does Revolution Medicines (NASDAQ:RVMD) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n

Simply Wall StMay 10 10:27 ET

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)

TipRanksMay 10 01:20 ET

Earnings Call Summary | Revolution Medicines(RVMD.US) Q1 2024 Earnings Conference

The following is a summary of the Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript:Financial Performance:Revolution Medicines reported a net loss of $116.0 million or $0.70 per share

moomoo AIMay 9 12:05 ET · Conference Call

Revolution Medicines Is Maintained at Outperform by Wedbush

Revolution Medicines Is Maintained at Outperform by Wedbush

Dow JonesMay 9 08:57 ET

Revolution Medicines (RVMD) Receives a Buy From Piper Sandler

TipRanksMay 9 06:54 ET

Express News | Needham Reiterates Buy on Revolution Medicines, Maintains $46 Price Target

BenzingaMay 9 06:46 ET

Revolution Medicines Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 20.07% Needham → $46 Reiterates Buy → Buy 04/12/2024 17.46% Oppenheimer $43 → $45 Maintains Out

BenzingaMay 9 06:45 ET

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Revolution Medicines (RVMD) and Personalis (PSNL)

TipRanksMay 9 06:40 ET

Express News | Revolution Medicines Inc : Guggenheim Raises Target Price to $50 From $38

ReutersMay 9 06:22 ET

Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

Yahoo FinanceMay 9 05:01 ET

Express News | Revolution Medicines Inc : Leerink Partners Raises Target Price to $48 From $37

ReutersMay 8 23:58 ET

Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 8 21:11 ET

Revolution Medicines Q1 2024 GAAP EPS $(0.70) Beats $(0.75) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.75) by 6.67 percent.

BenzingaMay 8 18:21 ET

Revolution Medicines Q1 Net Loss Narrows

Revolution Medicines (RVMD) reported a Q1 net loss Wednesday of $0.70 per share, narrowing from a loss of $0.72 a year earlier. Analysts polled by Capital IQ expected a loss of $0.75. The company did

MT NewswiresMay 8 17:37 ET

Revolution Medicines Reiterates Projected Full Year 2024 GAAP Net Loss To Be $(480)M-$(520)M

Based on the company's current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.

BenzingaMay 8 17:02 ET

Express News | Revolution Medicines Inc: Reiterating Projected 2024 Gaap Net Loss Between $480 Mln and $520 Mln

ReutersMay 8 16:51 ET